Literature DB >> 27654288

Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.

Nancy S Longo1, Matthew S Sutton1, Andrea R Shiakolas1, Javier Guenaga2, Marissa C Jarosinski1, Ivelin S Georgiev1,3, Krisha McKee1, Robert T Bailer1, Mark K Louder1, Sijy O'Dell1, Mark Connors4, Richard T Wyatt2, John R Mascola1, Nicole A Doria-Rose5.   

Abstract

One of the goals of HIV-1 vaccine development is the elicitation of neutralizing antibodies against vulnerable regions on the envelope glycoprotein (Env) viral spike. Broadly neutralizing antibodies targeting the Env glycan-V3 region (also called the N332 glycan supersite) have been described previously, with several single lineages each derived from different individual donors. We used a high-throughput B-cell culture method to isolate neutralizing antibodies from an HIV-1-infected donor with high serum neutralization breadth. Clonal relatives from three distinct antibody lineages were isolated. Each of these antibody lineages displayed modest breadth and potency but shared several characteristics with the well-characterized glycan-V3 antibodies, including dependence on glycans N332 and N301, VH4 family gene utilization, a heavy chain complementarity-determining region 2 (CDRH2) insertion, and a longer-than-average CDRH3. In contrast to previously described glycan-V3 antibodies, these antibodies preferentially recognized the native Env trimer compared to monomeric gp120. These data indicate the diversity of antibody specificities that target the glycan-V3 site. The quaternary binding preference of these antibodies suggests that that their elicitation likely requires the presentation of a native-like trimeric Env immunogen. IMPORTANCE: Broadly neutralizing antibodies targeting the HIV-1 glycan-V3 region with single lineages from individual donors have been described previously. Here we describe three lineages from a single donor, each of which targets glycan-V3. Unlike previously described glycan-V3 antibodies, these mature antibodies bind preferentially to the native Env trimer and weakly to the gp120 monomer. These data extend our knowledge of the immune response recognition of the N332 supersite region and suggest that the mode of epitope recognition is more complex than previously anticipated.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27654288      PMCID: PMC5110179          DOI: 10.1128/JVI.01012-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

3.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

4.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

5.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

6.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

7.  Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes.

Authors:  Bryan S Briney; Jordan R Willis; James E Crowe
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

8.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

9.  Large-scale analysis of human heavy chain V(D)J recombination patterns.

Authors:  Joseph M Volpe; Thomas B Kepler
Journal:  Immunome Res       Date:  2008-02-27

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  16 in total

1.  Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.

Authors:  Bharat Madan; Baoshan Zhang; Kai Xu; Cara W Chao; Sijy O'Dell; Jacy R Wolfe; Gwo-Yu Chuang; Ahmed S Fahad; Hui Geng; Rui Kong; Mark K Louder; Thuy Duong Nguyen; Reda Rawi; Arne Schön; Zizhang Sheng; Rajani Nimrania; Yiran Wang; Tongqing Zhou; Bob C Lin; Nicole A Doria-Rose; Lawrence Shapiro; Peter D Kwong; Brandon J DeKosky
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-09       Impact factor: 11.205

Review 2.  Targeting the N332-supersite of the HIV-1 envelope for vaccine design.

Authors:  Thandeka Moyo; Dale Kitchin; Penny L Moore
Journal:  Expert Opin Ther Targets       Date:  2020-04-27       Impact factor: 6.902

3.  Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan-dependent HIV-1 broadly neutralizing antibodies.

Authors:  Hui Cai; Jared Orwenyo; Javier Guenaga; John Giddens; Christian Toonstra; Richard T Wyatt; Lai-Xi Wang
Journal:  Chem Commun (Camb)       Date:  2017-05-03       Impact factor: 6.222

4.  Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Authors:  Shelly J Krebs; Young D Kwon; Chaim A Schramm; William H Law; Gina Donofrio; Kenneth H Zhou; Syna Gift; Vincent Dussupt; Ivelin S Georgiev; Sebastian Schätzle; Jonathan R McDaniel; Yen-Ting Lai; Mallika Sastry; Baoshan Zhang; Marissa C Jarosinski; Amy Ransier; Agnes L Chenine; Mangaiarkarasi Asokan; Robert T Bailer; Meera Bose; Alberto Cagigi; Evan M Cale; Gwo-Yu Chuang; Samuel Darko; Jefferson I Driscoll; Aliaksandr Druz; Jason Gorman; Farida Laboune; Mark K Louder; Krisha McKee; Letzibeth Mendez; M Anthony Moody; Anne Marie O'Sullivan; Christopher Owen; Dongjun Peng; Reda Rawi; Eric Sanders-Buell; Chen-Hsiang Shen; Andrea R Shiakolas; Tyler Stephens; Yaroslav Tsybovsky; Courtney Tucker; Raffaello Verardi; Keyun Wang; Jing Zhou; Tongqing Zhou; George Georgiou; S Munir Alam; Barton F Haynes; Morgane Rolland; Gary R Matyas; Victoria R Polonis; Adrian B McDermott; Daniel C Douek; Lawrence Shapiro; Sodsai Tovanabutra; Nelson L Michael; John R Mascola; Merlin L Robb; Peter D Kwong; Nicole A Doria-Rose
Journal:  Immunity       Date:  2019-03-12       Impact factor: 43.474

5.  HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope.

Authors:  Daniela Fera; Matthew S Lee; Kevin Wiehe; R Ryan Meyerhoff; Alessandro Piai; Mattia Bonsignori; Baptiste Aussedat; William E Walkowicz; Therese Ton; Jeffrey O Zhou; Samuel Danishefsky; Barton F Haynes; Stephen C Harrison
Journal:  Nat Commun       Date:  2018-03-16       Impact factor: 14.919

6.  Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine.

Authors:  Hui Cai; Roushu Zhang; Jared Orwenyo; John Giddens; Qiang Yang; Celia C LaBranche; David C Montefiori; Lai-Xi Wang
Journal:  ACS Cent Sci       Date:  2018-05-07       Impact factor: 14.553

Review 7.  The expanding array of HIV broadly neutralizing antibodies.

Authors:  Laura E McCoy
Journal:  Retrovirology       Date:  2018-10-16       Impact factor: 4.602

8.  Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

Authors:  Amelia Escolano; Harry B Gristick; Morgan E Abernathy; Julia Merkenschlager; Rajeev Gautam; Thiago Y Oliveira; Joy Pai; Anthony P West; Christopher O Barnes; Alexander A Cohen; Haoqing Wang; Jovana Golijanin; Daniel Yost; Jennifer R Keeffe; Zijun Wang; Peng Zhao; Kai-Hui Yao; Jens Bauer; Lilian Nogueira; Han Gao; Alisa V Voll; David C Montefiori; Michael S Seaman; Anna Gazumyan; Murillo Silva; Andrew T McGuire; Leonidas Stamatatos; Darrell J Irvine; Lance Wells; Malcolm A Martin; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Nature       Date:  2019-05-29       Impact factor: 49.962

9.  The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans.

Authors:  Dung N Nguyen; Richard L Redman; Satoru Horiya; Jennifer K Bailey; Bokai Xu; Robyn L Stanfield; J Sebastian Temme; Celia C LaBranche; Shiyu Wang; Avital A Rodal; David C Montefiori; Ian A Wilson; Isaac J Krauss
Journal:  ACS Chem Biol       Date:  2020-03-09       Impact factor: 5.100

Review 10.  Recent progress in broadly neutralizing antibodies to HIV.

Authors:  Devin Sok; Dennis R Burton
Journal:  Nat Immunol       Date:  2018-10-17       Impact factor: 31.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.